Call Us Today:
949.200.1600

Oral Systemic Therapy

Home  Treatment > Nonsurgical Treatment > Oral Systemic Therapy

SCARS-Center-Oral-Systemic-Therapy2

Oral Therapy FOR BASAL CELL CARCINOMA

Vismodegib (Erivedge)

Vismodegib has been approved for treatment of unresectable metastatic basal cell carcinomas. It comes as oral medication taken once again. It has been shown to be significantly effective in reducing and occasionally curing basal cell carcinomas. Its side effects are significant. They include loss of sense of taste, muscle cramps in upper and lower extremities, gastrointestinal side effects such as nausea, diarrhea, constipation, fatigue, and hair loss. Most of the side effects are reversible with stopping medication. Significant shortcoming of this medication is resistance of some basal cell carcinomas to the drug.
 
The length of treatment with Vismodegib can be variable and has not been well-established. Shortest courses can be as long as three months terminating due to the patient's intolerance of the side effects. Most courses run 7-9 months limited by the patient's intolerance of the drug. Surprisingly, some patients are able to tolerate the drug for over a year. The cost of the drug is significant up to $10,000 a month. Insurance companies cover the cost of the drug consistently. In cases of lack of insurance coverage, the manufacturers often provide the medication at no cost to the patient.
 
The mechanism of action is its effect on Sonic Hedgehog pathway. Vismodegib is the first SMO inhibitor molecule in its class. It binds and hinders SMO (transmembrane protein).
 

Sonidegib (Odomzo)

Sonidegib is also known by its chemical name erismodegib. It is also used for locally advanced basal cell carcinomas or metastatic basal cell carcinomas not amenable to surgery or radiation therapy. The mechanism of action is inhibition of smoothened protein. Its side effect profiles are similar to Vismodegib. It also suffers from development of resistances of the carcinomas. This drug is priced similarly to Vismodegib at approximately $10,000 per month.

 

Itraconazole (Sporanox)

Itraconazole is known as an antifungal drug. Due to its ability to inhibit Hedgehog pathway activity, it inhibits basal cell carcinoma growth. It has not been as widely evaluated for treatment of basal cell carcinoma as other Hedgehog inhibitors, although it is an older drug. Its feasibility in treating basal cell carcinomas and its dosing regimen are still being evaluated. It acts on SMO protein. It has also been called a Cilial translocation inhibitor. It is a powerful Hedgehog pathway inhibitor. It has similar side effect profile to the other Hedgehog inhibitors. This drug is also associated with resistance development by cancers.

 

ORAL THERAPY FOR SQUAMOUS CELL CARCINOMA

Capecitabine (Xeloda)

This chemotherapy agent is available as an oral medication. It is used primarily for squamous cell carcinomas. Its more common use is in gastrointestinal squamous cell carcinomas. The drug is converted intercellularly into 5-Fluorouracil. It is considered to be better tolerated form of 5-Fluorouracil than the IV 5-FU. Xeloda has been used for suppression of new squamous cell carcinomas in organ transplant recipients on chronic immunosuppressants.

 

Acitretin (Soriatane)

Acitretin is a vitamin A derivative, a retinoid normally prescribed for psoriasis. It had been found to be effective in treatment of extensive actinic keratosis. It decreases the frequency and thickness of actinic keratoses. Although some theorize it could decrease the frequency of squamous cell carcinomas, this has not been proven.

Related Articles

Upper-Chest-BCC-perineural-invasion-Mohs-and-closure-SCARS-center-wide-local-excision-SRT-radiotherapy-orange-county-skin-cancer.JPG
Upper Chest BCC PNI
HISTORY 53-year-old man presents with a 4-year-history of BCC of upper chest.  The tumor measured 12 cm x 6 cm. Wide local excision with 1 cm margins on 11/10/2017 found clear margins and perineural invasion. The nerves up to 0.23 mm were involved by tumor. The final defect was 13.5 cm x 8.3 cm.  …
Read More
BCC-SRT-superficial-radiation-therapy-orange-county-skin-cancer-basal-cell-carcinoma
Multiple Nasal BCCs
HISTORY 81-year-old man presents with 7-month history of two nasal tip and right nasal ala BCC’s. All three lesions were treated with 2 adjoining SRT fields. The course began 1-8-18 and completed by 1-26-18 after 15 treatments. DISCUSSION This patient represents an excellent candidate for radiation therapy. Electron beam radiation therapy can be used with…
Read More
Basal-cell-carcinoma-shave-excision-skin-cancer-orange-county-shave-excision-dermablade
Shave excision of Lower Extremity Carcinomas
HISTORY 67-year-old woman presents with 3 BCCs on right lower extremity diagnosed on shave biopsies.  Superficial shave excisions of the carcinomas left close margins within 0.1 mm. Second set of shave excisions found no residual carcinoma.     DISCUSSION Lower leg skin carcinomas are often superficial and can be treated with superficial treatments. This patient’s…
Read More
SCARS-Center-topical-5-fluorouracil-efficacy-in-basal-cell-carcinoma-skin-cancer1
Topical 5-fluorouracil and Imiquimod Efficacy in Basal and Squamous Cell Carcinomas
HISTORY 65-year-old woman presented in January 2017 with a nasal dorsum squamous cell carcinoma in situ. The nasal lesion was treated with 6 weeks of topical 5-fluorouracil with a robust inflammatory response. A separate chin basal cell carcinoma was simultaneously treated with 6 weeks of imiquimod prescribed in February, while still undergoing 5-fluorouracil on the…
Read More
1SCARS-Center-Field-Cancerization-with-basal-cell-carcinoma-skin-cancer-forehead (3)
FIELD CANCERIZATION WITH BASAL CELL CARCINOMA
2012 Radiation Simulation   Persistent cheek recurrence of BCC at edge of flap  recent CT showing resected right temporal bone with overlying flap and evidence of deep tumor HISTORY This 69-year-old man presented with greater than 25-year history of multiple basal cell carcinomas of the face and neck. His most problematic cancer has been in…
Read More
Medial-Canthus-Basal-Cell-Carcinoma-Follow Up-Skin-Cancer-And-Reconstructive-Surgery-Foundation1
MEDIAL CANTHUS BASAL CELL CARCINOMA FOLLOW UP
HISTORY 91 year old man presented with a recurrent right medial canthus BCC that was previously treated with 45 days of radiation (SRT at Hoag Hospital). Biopsy showed infiltrative sclerosing basal cell carcinoma with focal perineural invasion. MRI in December of 2016 showed the mass was fixed on the lamina papyracea adjacent to the medial…
Read More

STAY UP TO DATE

Receive research updates, inspiring stories, healthy living tips and more.

Something went wrong. Please check your entries and try again.

FOLLOW US

ELEVATING THE STANDARDS OF SKIN CANCER MANAGEMENT.

© 2018 SCARS Management Services. All rights reserved.